Code Pharma announced positive results from an eight-week clinical trial of Gammora, suggesting the drug’s potential to target HIV at the cellular level. Preliminary findings were shared at the 2024 HIV Drug Therapy Conference in Glasgow, Scotland.
Gammora is derived from HIV-1 integrase peptides and works by promoting the integration of viral genetic material into infected cells. In this open-label, randomized trial, combining Gammora with protease inhibitor (PI)-based antiretroviral therapy (ART) safely reduced the reservoir of HIV-infected cells without affecting healthy cells, a common challenge with standard ART drugs.
“These findings demonstrate Gammora’s safety and effectiveness as a new way forward in the evolving HIV functional cure landscape,” said Ricardo Sobhie Diaz, Federal University of Sao Paulo – UNIFESP, Brazil and principal investigator of the study.
These incredibly positive outcomes offer new hope at a time when 40 million individuals worldwide are impacted by HIV and the current standard of care with ART drugs does not offer a cure at the cellular level,” said Eynat Finkelshtein, PhD., Chief Scientific Officer of Code Pharma.